BMY Q4 Earnings and Sales Beat Estimates, Shares Down on 2025 Outlook

Core Viewpoint - Bristol-Myers Squibb Company (BMY) reported better-than-expected fourth-quarter 2024 results, but the outlook for 2025 is below expectations due to anticipated revenue declines from generic competition [1][2][18]. Financial Performance - Adjusted earnings per share (EPS) for Q4 2024 were $1.67, exceeding the Zacks Consensus Estimate of$1.46, but down from $1.70 in the same quarter last year [1]. - Total revenues reached$12.3 billion, surpassing the Zacks Consensus Estimate of $11.6 billion and reflecting an 8$48.3 billion, beating the Zacks Consensus Estimate of $47.5 billion [15]. Revenue Breakdown - U.S. revenues increased 9$8.6 billion, while international revenues grew 5% to $3.7 billion [4]. - The Growth Portfolio generated$6.4 billion in revenues, a 21% increase year-over-year, driven by strong sales of Reblozyl, Breyanzi, Camzyos, Yervoy, and Opdualag [5]. - Sales of Eliquis were $3.2 billion, up 11$547 million, outperforming estimates [7]. - Opdivo sales rose 4% to $2.48 billion but fell short of expectations [6]. - Breyanzi sales skyrocketed 160$263 million, significantly beating estimates [9]. Cost and Margin - Gross margin decreased to 74% from 76.4% year-over-year due to product mix changes [14]. - Adjusted research and development expenses increased 13% to $2.8 billion, while marketing and administrative expenses remained flat at$2.1 billion [14]. 2025 Guidance - The company expects adjusted EPS in the range of $6.55-$6.85 for 2025, below the Zacks Consensus Estimate of $6.98 [16]. - Projected revenues for 2025 are approximately$45.5 billion, reflecting a potential 18-20% decline in the Legacy Portfolio due to generic competition [16]. Strategic Initiatives - Bristol-Myers announced an expansion of its strategic productivity initiative, targeting approximately $2 billion in additional annualized cost savings by the end of 2027 [19].